H3K27 demethylation at the proviral promoter sensitizes latent HIV to the effects of vorinostat in ex Vivo cultures of resting CD4+ T cells

Journal of Virology

Volumn 89, Issue 16, 2015, Pages 8392-8405

  Tripathy, Manoj K ^a   McManamy, Mary E M ^a   Burch, Brandon D ^a   Archin, Nancie M ^a   Margolis, David M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; EZH1 PROTEIN; GAG PROTEIN; GSK 343; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; TRANSCRIPTION FACTOR EZH2; UNC 1999; UNCLASSIFIED DRUG; VIRUS RNA; VORINOSTAT; EZH1 PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; GSK343; HISTONE; HYDROXAMIC ACID; INDAZOLE DERIVATIVE; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONE DERIVATIVE; SMALL INTERFERING RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DEMETHYLATION; DRUG EXPOSURE; DRUG POTENTIATION; EX VIVO STUDY; HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; PROVIRUS; VIRUS LATENCY; ANALYSIS OF VARIANCE; ANTAGONISTS AND INHIBITORS; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOBLOTTING; METABOLISM; METHYLATION; PHYSIOLOGY; VIROLOGY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANALYSIS OF VARIANCE; CD4-POSITIVE T-LYMPHOCYTES; CHROMATIN IMMUNOPRECIPITATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONES; HIV; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; INDAZOLES; METHYLATION; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; PROVIRUSES; PYRIDONES; RNA, SMALL INTERFERING;

EID: 84938063312     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00572-15     Document Type: Article

References (55)

1. Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. 2014. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol 12:750-764. http://dx.doi.org/10.1038/nrmicro3352.
2. Siliciano RF, Greene WC. 2011. HIV latency. Cold Spring Harb Perspect Med 1:a007096. http://dx.doi.org/10.1101/cshperspect.a007096.
3. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94:13193-13197. http://dx.doi.org/10.1073/pnas.94.24.13193.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300. http://dx.doi.org/10.1126/science.278.5341.1295.
5. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295. http://dx.doi.org/10.1126/science.278.5341.1291.
6. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
7. Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, ten Berge IJ, Yong SL, Fox CH, Roos MT, de Wolf F, Goudsmit J, Schuitemaker H, Lange JM. 1999. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405-2410. http://dx.doi.org/10.1097/00002030-199912030-00012.
8. Hakre S, Chavez L, Shirakawa K, Verdin E. 2011. Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 6:19-24. http://dx.doi.org/10.1097/COH.0b013e3283412384.
9. Mbonye U, Karn J. 2011. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 9:554-567. http://dx.doi.org/10.2174/157016211798998736.
10. Tripathy MK, Abbas W, Herbein G. 2011. Epigenetic regulation of HIV-1 transcription. Epigenomics 3:487-502. http://dx.doi.org/10.2217/epi.11.61.
11. Van Lint C, Emiliani S, Ott M, Verdin E. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112-1120.
12. Verdin E, Paras P, Jr, Van Lint C. 1993. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12:3249-3259.
13. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U, Margolis DM. 2000. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 74:6790-6799. http://dx.doi.org/10.1128/JVI.74.15.6790-6799.2000.
14. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM. 2009. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 83:4749-4756. http://dx.doi.org/10.1128/JVI.02585-08.
15. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. 2006. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 25:139-149. http://dx.doi.org/10.1038/sj.emboj.7600900.
16. Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. 2011. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett 585:3549-3554. http://dx.doi.org/10.1016/j.febslet.2011.10.018.
17. du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P, Bertrand E, Marcello A, Emiliani S, Kiernan R, Benkirane M. 2007. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J 26:424-435. http://dx.doi.org/10.1038/sj.emboj.7601517.
18. Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J. 2011. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 85:9078-9089. http://dx.doi.org/10.1128/JVI.00836-11.
19. Imai K, Togami H, Okamoto T. 2010. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 285:16538-16545. http://dx.doi.org/10.1074/jbc.M110.103531.
20. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D, Rohr O. 2007. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing.EMBOJ 26:412-423. http://dx.doi.org/10.1038/sj.emboj.7601516.
21. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 25: 207-212. http://dx.doi.org/10.1089/aid.2008.0191.
22. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. 2009. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 23:1799-1806. http://dx.doi.org/10.1097/QAD.0b013e32832ec1dc.
23. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. http://dx.doi.org/10.1038/nature11286.
24. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. 2009. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284:6782-6789. http://dx.doi.org/10.1074/jbc.M807898200.
25. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP. 2009. Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 25:883-887. http://dx.doi.org/10.1089/aid.2008.0294.
26. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sekaly RP, Lewin SR. 2014. Activation of HIV transcription with short-course vorinostat in HIVinfected patients on suppressive antiretroviral therapy. PLoS Pathog 10: e1004473. http://dx.doi.org/10.1371/journal.ppat.1004473.
27. Matalon S, Palmer BE, Nold MF, Furlan A, Kassu A, Fossati G, Mascagni P, Dinarello CA. 2010. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) Tcells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 54:1-9. http://dx.doi.org/10.1097/QAI.0b013e3181d3dca3.
28. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M. 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-e21. http://dx.doi.org/10.1016/S2352-3018(14)70014-1.
29. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, De Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, Van Lint C. 2009. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4:e6093. http://dx.doi.org/10.1371/journal.pone.0006093.
30. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T. 2014. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10:e1004071. http://dx.doi.org/10.1371/journal.ppat.1004071.
31. Ying H, Zhang Y, Lin S, Han Y, Zhu HZ. 2010. Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines. Int J Mol Med 26:265-272.
32. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. 2004. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18:1101-1108. http://dx.doi.org/10.1097/00002030-200405210-00003.
33. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20:425-429. http://dx.doi.org/10.1038/nm.3489.
34. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Jr, Coffin JM, Mellors JW. 2014. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 111:7078-7083. http://dx.doi.org/10.1073/pnas.1402873111.
35. Colin L, Van Lint C. 2009. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111. http://dx.doi.org/10.1186/1742-4690-6-111.
36. Beisel C, Paro R. 2011. Silencing chromatin: comparing modes and mechanisms. Nat Rev Genet 12:123-135. http://dx.doi.org/10.1038/nrg2932.
37. Margueron R, Reinberg D. 2011. The Polycomb complex PRC2 and its mark in life. Nature 469:343-349. http://dx.doi.org/10.1038/nature09784.
38. Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, Romeril SP, Burgess JL, Grant SW, Brackley JA, Graves AP, Scherzer DA, Shu A, Thompson C, Ott HM, Aller GS, Machutta CA, Diaz E, Jiang Y, Johnson NW, Knight SD, Kruger RG, McCabe MT, Dhanak D, Tummino PJ, Creasy CL, Miller WH. 2012. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACSMedChem Lett 3:1091-1096. http://dx.doi.org/10.1021/ml3003346.
39. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD, Wong KK, Cerchietti L, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, Melnick AM. 2013. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23:677-692. http://dx.doi.org/10.1016/j.ccr.2013.04.011.
40. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. 2007. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110:4161-4164. http://dx.doi.org/10.1182/blood-2007-06-097907.
41. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254. http://dx.doi.org/10.1016/0003-2697(76)90527-3.
42. Pearson R, Kim YK, Hokello J, Lassen K, Friedman J, Tyagi M, Karn J. 2008. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol 82:12291-12303. http://dx.doi.org/10.1128/JVI.01383-08.
43. Kutsch O, Benveniste EN, Shaw GM, Levy DN. 2002. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 76:8776-8786. http://dx.doi.org/10.1128/JVI.76.17.8776-8786.2002.
44. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M, Jiang A, Pattenden SG, Norris JL, James LI, Roth BL, Brown PJ, Frye SV, Arrowsmith CH, Hahn KM, Wang GG, Vedadi M, Jin J. 2013. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 8:1324-1334. http://dx.doi.org/10.1021/cb400133j.
45. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C. 2012. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 26: 1473-1482. http://dx.doi.org/10.1097/QAD.0b013e32835535f5.
46. Kim YK, Bourgeois CF, Pearson R, Tyagi M, West MJ, Wong J, Wu SY, Chiang CM, Karn J. 2006. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J 25: 3596-3604. http://dx.doi.org/10.1038/sj.emboj.7601248.
47. Bosque A, Planelles V. 2011. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 53:54-61. http://dx.doi.org/10.1016/j.ymeth.2010.10.002.
48. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, Greene WC, Kashuba A, Lewin SR, Margolis DM, Mau M, Ruelas D, Saleh S, Shirakawa K, Siliciano RF, Singhania A, Soto PC, Terry VH, Verdin E, Woelk C, Wooden S, Xing S, Planelles V. 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9:e1003834. http://dx.doi.org/10.1371/journal.ppat.1003834.
49. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45. http://dx.doi.org/10.1038/47412.
50. + T cells from infected individuals receiving antiretroviral therapy. J Virol 86:5390-5392. http://dx.doi.org/10.1128/JVI.00040-12.
51. Matsuda Y, Kobayashi-Ishihara M, Fujikawa D, Ishida T, Watanabe T, Yamagishi M. 2015. Epigenetic heterogeneity in HIV-1 latency establishment. Sci Rep 5:7701. http://dx.doi.org/10.1038/srep07701.
52. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M. 2012. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92:1147-1154. http://dx.doi.org/10.1189/jlb.0312165.
53. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. 2012. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 287: 36609-36616. http://dx.doi.org/10.1074/jbc.M112.410746.
54. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li PC, Planelles V, Bradner JE, Zhou MM, Siliciano RF, Weinberger L, Verdin E, Ott M. 2013. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12:452-462. http://dx.doi.org/10.4161/cc.23309.
55. Ribrag V, Soria JC, Reyderman L, Chen R, Salazar P, Kumar N, Kuznetsov G, Keilhack H, Ottesen LH, Italiano A. 2014. Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma. Eur J Cancer 50(Suppl 6):197.